Tygacil

TYGACI Tygacil (tigecycline) is an antibacterial drug that was approved in 2005. The drug is administered through IV to treat Staph infections. It is not approved to treat hospital-acquired pneumonia or diabetes-related foot infections. INFECTION Alleged Side Effects STAPH Anaphylaxis, Rapid Swelling of the Face and Throat Acute Pancreatitis Liver Problems, Jaundice and Cholestasis Severe Skin Reactions, Stevens Johnson Syndrome (SJS) In 2010, the FDA warned that Tygacil increases the risk of death. Wrongful Death TYGACIL Recover For Your Losses In 2013, the FDA added a “Black Box" warning to the drug. Medical Bills Lost Income Pain and Suffering Loss of Consortium (If Applicable) Wrongful Death (If Applicable) Call d'Oliveira & Associates at 1-800-992-6878 for a free Consultation TI|||||